DUBLIN--(
BUSINESS WIRE
)--The
"2022 What's Next for World Tumor Marker Testing Market - High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers"
report has been added to
ResearchAndMarkets.com's
offering.
The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.
During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Regions
Asia-Pacific, Europe, Latin America, Middle East, North America
Country Analyses
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Egypt, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
Business Opportunities and Strategic Recommendations
Specific new product development opportunities with potentially significant market appeal during the next five years.
Design criteria for new products.
Alternative market penetration strategies.
Potential market entry barriers and risks.
Over 200 Current and Emerging Cancer Diagnostic Tests
Oncogenes
Biochemical Markers
Growth Factors
Colony Stimulating Factors
Hormones
Immunohistochemical Stains
Lymphokines
ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
Supplier Shares, Sales and Volume Forecasts
Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test.
Five-year test volume and sales forecasts for major cancer diagnostic assays.
Instrumentation Review
Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
Technology Assessment
Assessment of latest technologies and their potential applications for cancer diagnostic testing.
Review of competing/complementing technologies.
Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Strategies
Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
The companies analyzed in the report include:
Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, Ortho-Clinical Diagnostics, Perkin Elmer, Qiagen, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others.
For more information about this report visit
https://www.researchandmarkets.com/r/ffjqzd
